A study found that patent settlements between the makers of branded and generic drugs elevate prices across the spectrum of treatments in a therapeutic area. The unavailability of generic copies of a brand-name attention-deficit/hyperactivity disorder drug led to greater price increases in other ADHD treatments, researchers concluded. The results suggest that efforts to probe and prohibit patent settlements are justified, researcher Farosat Bokhari said.

Full Story:
PMLive.com (U.K.)

Related Summaries